Full macular translocation for choroidal neovascularization in the era of intravitreal pharmacological therapy.
Vitreoretinal Department, AZ Sint-Augustinus, Antwerp, Belgium. greghaver@hotmail.com
Greg M
GM
Haverbeke
Carl
C
Claes
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000637:transplantation*; D008268:Macular Degeneration / Q000503:physiopathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D013508:Ophthalmologic Surgical Procedures; D011446:Prospective Studies; D013459:Sulfur Hexafluoride / Q000008:administration & dosage; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D014792:Visual Acuity / Q000502:physiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D010959:Tissue Plasminogen Activator; D013459:Sulfur Hexafluoride